Holen Sie sich die Stockscreener-App
13.34
2.06%
-0.28
Schlusskurs vom Vortag:
$13.62
Offen:
$13.69
24-Stunden-Volumen:
753.95K
Relative Volume:
0.97
Marktkapitalisierung:
$869.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.67M
KGV:
-4.8864
EPS:
-2.73
Netto-Cashflow:
$-97.30M
1W Leistung:
-8.76%
1M Leistung:
-1.04%
6M Leistung:
+30.91%
1J Leistung:
-2.41%
1-Tages-Spanne:
$13.28
$13.90
1-Wochen-Bereich:
$13.28
$14.80
52-Wochen-Spanne:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER ROAD, RADNOR
Vergleichen Sie MLYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.34 | 952.86M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - jammulinksnews.com
What drives Mineralys Therapeutics Inc. stock priceMassive portfolio appreciation - Autocar Professional
What analysts say about Mineralys Therapeutics Inc. stockMarket-crushing profits - jammulinksnews.com
Is Mineralys Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN
(MLYS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Mineralys Therapeutics CFO Adam Levy sells $155k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Congleton sells $230k in shares By Investing.com - Investing.com South Africa
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mineralys Therapeutics, Inc. (MLYS) Receives a Hold from Jefferies - The Globe and Mail
Jefferies Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $15 - 富途牛牛
Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success - TipRanks
Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data By Investing.com - Investing.com South Africa
Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data - Investing.com Australia
Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com
Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN
Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo.co
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Mineralys reports positive phase 3 results for hypertension drug By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener
Mineralys’ Drug Significantly Cut Blood Pressure in Key Study - Bloomberg
(MLYS) Long Term Investment Analysis - news.stocktradersdaily.com
Is Mineralys Therapeutics, Inc. technically bullish or bearish? - MarketsMojo
Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca - insights.citeline.com
Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension - Pharmacy Times
Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada
Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter
Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal - TipRanks
Mineralys reports positive phase 2 data for lorundrostat in CKD By Investing.com - Investing.com South Africa
Mineralys reports positive phase 2 data for lorundrostat in CKD - Investing.com Australia
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):